Originally published by our sister publication Infectious Disease Special Edition
The FDA approved lenacapavir (Sunlenca, Gilead), in combination with other antiretroviral(s) (ARV) for the treatment of HIV-1 in heavily treatment-experienced adults with multidrug-resistant (MDR) infection.
The approval for lenacapavir, a first-in-class, long-acting HIV capsid inhibitor that is injected twice yearly, is supported by data from the phase 2/3 CAPELLA trial. The study evaluated lenacapavir with